See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Gilead Sciences Inc. (GILD - Free Report) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating its experimental once-daily integrase strand transfer inhibitor (INSTI), bictegravir (GS-9883), for the treatment of HIV-1 infection. Data were presented at the American Society of Microbiology Conference.
Results showed that bictegravir demonstrated a favorable pharmacokinetics and resistance profile when compared to currently available INSTIs – Tivicay (dolutegravir), Vitekta (elvitegravir) and Isentress (raltegravir). While bictegravir alone was highly effective against HIV-1 infected target cells, in combination with tenofovir alafenamide (TAF), Emtriva (emtricitabine) and Prezista (darunavir), it was highly synergistic against HIV-1. On the safety front, it was found to be well tolerated with no serious adverse events (AEs) and no discontinuations due to AEs.
We note that a single tablet regimen of bictegravir is currently being evaluated in phase III studies in combination with TAF and Emtriva for the treatment of HIV-1 infection.
HIV is Gilead’s one of the primary areas of focus. The company has three other TAF-based regimens that recently gained FDA approval for the treatment of HIV-1 infection – Descovy, Odefsey and Genvoya. While Genvoya and Descovy are already approved in the EU, Odefsey is under review in the same.
Gilead is a Zacks Rank #5 (Strong Sell) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>